Status:
COMPLETED
Efficacy of Bimatoprost 0.03% in Patients Who Are Low-Responders to Latanoprost
Lead Sponsor:
Innovative Medical
Conditions:
Glaucoma
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
To evaluate the IOP-lowering efficacy of bimatoprost 0.03% in patients found to be low-responders to latanoprost therapy.
Eligibility Criteria
Inclusion
- · Male or female \> 18 years of age
- Documented low-responder to latanoprost therapy as delineated in the outline above.
- Diagnosis of open-angle glaucoma or ocular hypertension
- Ability to provide informed consent and likely to complete all study visits
Exclusion
- · Known contraindication to bimatoprost or any component of any study medication
- Uncontrolled systemic disease
- Active ocular disease other than glaucoma or ocular hypertension
- Required use of ocular medications other than the study medications during the study (intermittent use of artificial tear solutions will be permitted)
- History of intraocular surgery within the last 3 months
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00347841
Last Update
June 1 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dr. Noecker
Pittsburgh, Pennsylvania, United States, 15213